Assize Index

Azúcares y edulcorantes

Sacarina

GI(Glucose = 100)

Principal · 0 GI

High-intensity sweeteners — no available carbohydrate for classical GI (2020)

Energy(kcal/100g)

Principal · 0 kcal/100g

High-intensity sweeteners — no available carbohydrate for classical GI (2020)

Carbs(g/100g)

Principal · 0 g/100g

High-intensity sweeteners — no available carbohydrate for classical GI (2020)

Sugars(g/100g)

Principal · 0 g/100g

High-intensity sweeteners — no available carbohydrate for classical GI (2020)

Beneficios funcionales

Todavía no hay minerales citados ni otras notas funcionales.

Los minerales citados pueden sumar hasta +2 en El mejor endulzante para el día a día — ver Methods.

Riesgos y efectos secundarios

  • Edulcorante de alta intensidad

    note

    Use-level and blends matter. Packet fillers are different products. Regulatory class note — not scored.

    FDA — High-intensity sweeteners permitted for use in food (2023)

  • OMS: no para controlar el peso

    caution

    WHO 2023, conditional (low certainty): not for weight control or lowering disease risk — no long-term body-fat benefit. Not a safety ruling. Scored: the energy points it earns over sucrose are taken back on Everyday Health, Weight goals and Easy on the liver; not on Diabetic-friendly (WHO excludes people with diabetes).

    WHO — Use of non-sugar sweeteners: WHO guideline (2023)

  • Respuesta de glucosa alterada (ensayo de 2 semanas)

    note

    Cell 2022 randomized trial: saccharin impaired glucose tolerance in healthy adults (20 per arm, 2 weeks, below ADI); aspartame and stevia did not. Small and short, a lab measure rather than a disease outcome, and the sachets carried glucose. Contrary trial in Notes (Serrano 2021). Scored: glucose signal −7 on Everyday Health and Weight goals (not on Easy on the liver; synthetics are not on Diabetic-friendly).

    Suez et al. — Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance (Cell) (2022)

No es consejo médico. Las penalizaciones publicadas, cuando existen, se explican en Cómo puntuamos y no representan una escala clínica de gravedad.

Notas

  • Contrary trial: pure saccharin at the maximum ADI for 2 weeks (46 healthy adults, double-blind) changed neither glucose tolerance nor gut microbiota. We still score the glucose signal from Cell 2022 and print this beside it.

    Capsules without a glucose vehicle; Cell 2022 sachets carried glucose. Two short trials disagree — neither measured a disease outcome.

    Serrano et al. — High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice (Microbiome) (2021)

Las notas explican lo que el eje abierto o las etiquetas de riesgo por sí solos no muestran; no es consejo médico.

Una celda vacía indica que aún no disponemos de una fuente que describa el método. El primer puesto responde a la regla publicada, no a un veredicto médico.